Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/76775
| DC Field | Value | Language |
|---|---|---|
| dc.contributor | Department of Applied Biology and Chemical Technology | - |
| dc.creator | Chow, LMC | - |
| dc.creator | Chan, TH | - |
| dc.creator | Chan, KF | - |
| dc.creator | Wong, ILK | - |
| dc.creator | Law, MC | - |
| dc.date.accessioned | 2018-06-13T02:56:14Z | - |
| dc.date.available | 2018-06-13T02:56:14Z | - |
| dc.identifier.uri | http://hdl.handle.net/10397/76775 | - |
| dc.language.iso | en | en_US |
| dc.rights | Assignee: The Hong Kong Polytechnic University | en_US |
| dc.rights | Assignee: McGill University | en_US |
| dc.title | Alkyne-, azide- and triazole-containing flavonoids as modulators for multidrug resistance in cancers | en_US |
| dc.type | Patent | en_US |
| dc.description.otherinformation | US9611256; US9611256 B2; US9611256B2; US9,611,256; US 9,611,256 B2; 9611256; Appl. No. 14/378,869 | en_US |
| dcterms.abstract | A triazole bridged flavonoid dimer compound library was efficiently constructed via the cycloaddition reaction of a series of flavonoid-containing azides (Az 1-15) and alkynes (Ac 1-17). These triazole bridged flavonoid dimers and their precursor alkyne- and azide-containing flavonoids were screened for their ability to modulate multidrug resistance (MDR) in P-gp-overexpressed cell line (LCC6MDR), MRP1-overexpressed cell line (2008/MRP1) and BCRP-overexpressed cell line (HEK293/R2 and MCF7-MX100). Generally, they displayed very promising MDR reversal activity against P-gp-, MRP1- and BCRP-mediated drug resistance. Moreover, they showed different levels of selectivity for various transporters. Overall, they can be divided into mono-selective, dual-selective and multi-selective modulators for the P-gp, MRP1 and BCRP transporters. The EC50 values for reversing paclitaxel resistance (141-340 nM) of LCC6MDR cells, DOX (78-590 nM) and vincristine (82-550 nM) resistance of 2008/MRP1 cells and topotecan resistance (0.9-135 nM) of HEK293/R2 and MCF7-MX100 cells were at nanomolar range. Importantly, a number of compounds displayed EC50 at or below 10 nM in BCRP-overexpressed cell lines, indicating that these bivalent triazoles more selectively inhibit BCRP transporter than the P-gp and MRP1 transporters. Most of the dimers are notably safe MDR chemosensitizers as indicated by their high therapeutic index values. | - |
| dcterms.bibliographicCitation | US Patent 9,611,256 B2. Washington, DC: US Patent and Trademark Office, 2017. | - |
| dcterms.issued | 2017-04-04 | - |
| dc.identifier.ros | 2016002111 | - |
| dc.description.country | US | - |
| dc.identifier.rosgroupid | 2016002068 | - |
| dc.description.ros | 2016-2017 > Other Outputs > Patents granted | - |
| dc.description.validate | 201806 bcrc | - |
| dc.description.oa | Version of Record | en_US |
| Appears in Collections: | Patent | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| us9611256b2.pdf | 4.29 MB | Adobe PDF | View/Open |
Page views
169
Last Week
0
0
Last month
Citations as of Nov 30, 2025
Downloads
106
Citations as of Nov 30, 2025
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.


